Expressing enthusiasm for the appointment, Peptonic's CEO looks forward to welcoming Jenni to the company. "Jenni brings with her a solid experience in finance and possesses a profound understanding of both public companies and the life science industry. I am confident that her experience and expertise will significantly contribute to Peptonic's continued development," says
Jenni joins Peptonic from
During the transition period, Daniel Rudeklint will undertake the role of Acting CFO. Daniel, currently a board member of Peptonic, possesses a deep understanding of the company's operations. With experience as both CEO and CFO, as well as holding board positions in both listed and unlisted companies, Daniel brings invaluable expertise to his interim role.
For further information, please contact:
Anna Linton, CEO
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic
Central to the growth strategy is the geographical expansion of VagiVital and Verniva through local partners. Peptonic Medical also intends to continuously broaden the company's product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries
https://news.cision.com/peptonic-medical-ab/r/jenni-bjornulfson-appointed-as-new-cfo-of-peptonic-medical,c3982113
(c) 2024 Cision. All rights reserved., source